Revium Rx appoints Amir Avraham permanent CEO, Shlomi Schwartzblat as Chairman

Revium Rx.

Appointed Amir Avraham as permanent CEO (was interim since May 2025), effective Feb 1, 2026.
Monthly salary of NIS 55,000; eligible for annual discretionary bonus and one-time $50,000 bonus if $5M equity raised within 18 months.
Option grant of 1,300,000 shares vesting from Feb 1, 2026; additional 300,000 upon $3M investments, and 300,000 upon M&A completion.
Appointed Shlomi Schwartzblat as Director and Chairman of the Board, effective immediately, term through 2026 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.